High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.
about
Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia AGene therapy for haemophiliaGene therapy for haemophiliaDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroPractical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.The use of desmopressin in acquired haemophilia A: a systematic review.Menorrhagia from a haematologist's point of view. Part I: initial evaluation.Menorrhagia from a haematologist's point of view. Part II: management.The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres.The utility of the DDAVP challenge test in children with low von Willebrand factor.Current understanding of von Willebrand's disease in women - some answers, more questions.The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization.How do you treat bleeding disorders with desmopressin?The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre.Use of recombinant factor VIIa in inherited and acquired von Willebrand disease.von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.Endometrial haemostasis and menstruation.Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.Von Willebrand's disease: case report and review of literature.von Willebrand disease and other disorders of hemostasis in the patient with menorrhagia.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders.Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.Side effects of desmopressin in patients with bleeding disorders.Guidelines for the management of hemophilia.Desmopressin in moderate hemophilia A patients: a treatment worth considering.
P2860
Q24187454-9B46C261-0E43-4F08-A58E-00E6B2CA85A3Q24187977-02D233E8-D129-4015-AEB7-11FC173547E3Q24202755-FF5119F1-A609-4653-91CB-9CD0893166B3Q30315531-3DBE22C3-FEA6-4D99-9AB4-563C491FC4EBQ33424718-D5D6D996-3C32-45E3-B471-DB6BD7539DDBQ34207741-9CA11B83-1467-4EDA-A4CA-220A95C57AD8Q34637026-6FD51040-784C-40F0-9BAE-8771799AD3BEQ34637033-1FF26824-0862-4987-9F78-413262D8DD2DQ34816051-6B8D2369-FC90-4DCB-B838-4C3795D57465Q35743642-707D7CFE-CF74-4865-9069-1E3312931EF6Q36021374-6AACBD78-A60B-401F-A703-EF086043F5B6Q36473099-5DE79F28-21AC-4B70-B59F-22B526BBC018Q36533439-201546DE-B3C7-4F45-BCA5-510A4B30E6CCQ36754092-D055B018-6A14-4C6E-BA7E-1BB1D6CE7005Q36945964-D942FE93-3129-4DBC-BC6E-A6B8B8B85536Q37080746-1CE74A88-F4F2-422A-9C48-40139B70B5F7Q37100261-A94DE03C-FFFD-4443-83CC-B5D83CD472CCQ37124978-2515F674-6DDE-45DF-95B6-7F1EAF6F2811Q37357218-D6C4A40B-2BE2-4B14-BC84-8642DAB44C86Q38062471-4DBB16C6-0722-4485-89D4-5EFB45464144Q38128397-F2EF38FE-2A74-4DED-BED2-653DBEA6CE65Q41495178-D9E621FA-8CFD-4959-88FA-7DE1B567BC0FQ43267078-A086A29D-CF9B-406B-8748-993DFA447E32Q44211358-79F0660D-EBFD-4EEE-916F-24E549A2AC2EQ45871245-DE7FA59D-9F8F-42CC-B067-F3CFBD77E849Q45875278-FAC7A605-AD0D-4D72-8FE7-596C2EB5C70AQ45875630-D0E41E1B-C97B-42BA-8E11-03C4F93E5BE2Q45876486-486851B7-4A2D-457B-A013-6BFD50A15543Q45880345-A9FC3203-8F47-4308-A0F6-A40007E5379AQ47203639-D729AD46-D25B-48B6-9A61-C6D360B346EE
P2860
High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@ast
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@en
type
label
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@ast
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@en
prefLabel
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@ast
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@en
P2093
P2860
P1433
P1476
High-dose DDAVP intranasal spr ...... tic carriers of haemophilia A.
@en
P2093
Cornell C Jr
Cox Gill J
Leissinger C
P2860
P304
P356
10.1046/J.1365-2516.2001.00500.X
P577
2001-05-01T00:00:00Z